Literature DB >> 1984747

National Education Programs Working Group report on the management of patients with hypertension and high blood cholesterol.

.   

Abstract

Cardiovascular diseases are responsible for nearly one of every two deaths in the United States, and have been estimated to cost more than $127 billion annually. Epidemiologic data have shown that persons with fewer or lower levels of the risk factors for cardiovascular disease are less likely to have a cardiovascular event. In addition, the greater the level of any single risk factor, the greater is the chance of incurring disease. Moreover, a combination of risk factors creates a synergistic effect, further increasing risk. Conversely, reducing the number and level of risk factors prevents death and disability from cardiovascular diseases. This report addresses the management of patients with several cardiovascular risk factors, placing a special emphasis on hypertension and high blood cholesterol. Nonpharmacologic therapy, in the form of proper diet, exercise, and smoking cessation, is the foundation for management of both hypertension and high blood cholesterol. Clinicians should use these nondrug measures as definitive or adjunctive therapy. Pharmacologic agents can be very beneficial in managing the risks imposed by elevated levels of blood pressure or blood cholesterol. In selecting medications, it is important to weight their benefits, costs, and potential untoward effects. Clinicians must consider these issues in managing patients with several risk factors but should not avoid managing any risk factor or quickly dismiss any particular mode of therapy simply because of the potential for adverse effects.

Entities:  

Mesh:

Year:  1991        PMID: 1984747     DOI: 10.7326/0003-4819-114-3-224

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease.

Authors:  Aram V Chobanian
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

Review 2.  Current strategies in the diagnosis and management of lower extremity peripheral vascular disease.

Authors:  T J Wilt
Journal:  J Gen Intern Med       Date:  1992 Jan-Feb       Impact factor: 5.128

Review 3.  Drug utilisation review and pharmacoeconomics: interaction after parallel development?

Authors:  S Garattini; G Tognoni
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

4.  Costs of antihypertensive therapy.

Authors:  A L Hume
Journal:  J Gen Intern Med       Date:  1991 Jul-Aug       Impact factor: 5.128

Review 5.  Maternal involvement in the development of cardiovascular phenotype.

Authors:  R McCarty; M A Cierpial; C A Murphy; J H Lee; C Fields-Okotcha
Journal:  Experientia       Date:  1992-04-15

6.  The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects.

Authors:  L Ziviani; L Da Ros; L Squassante; S Milleri; M Cugola; L E Iavarone
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

7.  How Hypertension Guidelines Address Social Determinants of Health: A Systematic Scoping Review.

Authors:  Na'amah Razon; Danielle Hessler; Kirsten Bibbins-Domingo; Laura Gottlieb
Journal:  Med Care       Date:  2021-12-01       Impact factor: 2.983

8.  LIPITENSION: Interplay between dyslipidemia and hypertension.

Authors:  Jamshed J Dalal; T N C Padmanabhan; Piyush Jain; Shiva Patil; Hardik Vasnawala; Ashish Gulati
Journal:  Indian J Endocrinol Metab       Date:  2012-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.